恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

交易中 11-09 11:22:26

51.000

-1.200

-2.30%

最高52.600	最低50.950	成交量68.89万
今开52.600	昨收52.200	日振幅3.16%
总市值3,385亿	流通市值131.58亿	总股本66.37亿
成交额3,553万	换手率0.27%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":51,"timestamp":1794194526488,"preClose":52.2,"halted":0,"volume":688904,"delay":0,"changeRate":-0.02298850574712649,"floatShares":258000000,"shares":6637000000,"eps":1.3865485768054573,"marketStatus":"交易中","change":-1.2,"latestTime":"11-09 11:22:26","open":52.6,"high":52.6,"low":50.95,"amount":35526127,"amplitude":0.031609,"askPrice":51,"askSize":11800,"bidPrice":50.95,"bidSize":12400,"shortable":3,"etf":0,"ttmEps":1.5735411029640083,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1794196800000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":52.2,"dividendRate":0.004629,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":0.507515,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":49.66,"timestamp":1794194544000,"preClose":50.43,"halted":0,"volume":30236800,"delay":0,"premium":"-12.60"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2682214148","title":"港股概念追踪 | 欧洲资本组团来华扫货 中国创新药迈向海外商业化4.0时代(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682214148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682214148?lang=zh_cn&edition=full","pubTime":"2026-11-09 07:18","pubTimestamp":1794179936,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，在上海举办的“FHIM2026全球医药合作与投资年会”上，10余家欧洲生命科学投资机构的负责人组团而来，目的是挖掘中国创新药产业链中的好资产。欧洲对中国药企具备突出的战略价值。另外，从产业互补的角度看，欧洲拥有的科研积淀、产业经验与资本生态，是中国创新药实现全球化升级的重要支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK1583","LU0359202008.SGD","LU1251922891.USD","LU2328871848.SGD","BK1515","BK4585","BK1588","BK4588","BK1500","LU1770034418.SGD","LU1303224171.USD","LU1023057109.AUD","LU0359201612.USD","BK1574","LU0228659784.USD","LU1719994722.HKD","BK1191","LU1969619763.USD","01877","01276","VXUS","06160","LU0588546209.SGD","LU2543165471.USD","BK1161","LU0828237510.HKD","LU0359201885.HKD","KURE","KCAI","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118811495","title":"恒瑞医药（01276）2025年A股员工持股计划首期解锁471.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118811495","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118811495?lang=zh_cn&edition=full","pubTime":"2026-11-06 19:45","pubTimestamp":1793965538,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司的2025年A股员工持股计划首个12个月锁定期将于2026年11月7日届满。根据公司11月6日发布的公告，因公司层面与个人层面考核指标均已达标，首期可解锁股份数量为471.37万股，占公司总股本的0.07%，涉及持有人1,127名。公告显示，公司于2025年11月6日已通过非交易过户方式，将1,351.11万股公司股份划入员工持股计划账户。公司称，将按法规要求持续披露员工持股计划的后续进展，提醒投资者关注相关风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113237150","title":"恒瑞医药：摩根大通同日披露权益变动，好仓比例降至9.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113237150","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113237150?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:15","pubTimestamp":1793956526,"startTime":"0","endTime":"0","summary":"摩根大通于2026年11月3日以每股均价50.5085港元场外卖出恒瑞医药股份246.63万股，涉资约1.25亿港元；该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。同日，摩根大通归还某证券借贷协议下借入的恒瑞医药股份，减少淡仓；该情形并非在联交所公开市场直接买卖，归类为其他非交易性变动。摩根大通此次减持前持有恒瑞医药好仓2694.27万，占比10.43%；减持后持股量为2447.64万，好仓比例降至9.47%。同期，淡仓由918.42万减少至670.40万。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681539988","title":"中国女首富夫妻各有千亿家业，39岁独生女接谁的班 | 棱镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2681539988","media":"棱镜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681539988?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:59","pubTimestamp":1793951940,"startTime":"0","endTime":"0","summary":"但夫妻二人各自担任一家企业的董事长，各自登台为自己企业IPO敲锣，实属罕见。39岁独生女，接父母谁的班？这一年，她28岁。在官方发布的新闻稿中，代表公司对外发声的，是39岁的执行董事孙远。截至最新公告，岑均达在英属维京群岛的家族信托，持有翰森制药15.16%的股权，仅次于钟慧娟母女的Sunrise信托。这一年，她35岁。获奖人名单中，位列第二、第三的，分别是岑均达和吕爱锋。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3MTY0MTQzNg==&mid=2650277745&idx=1&sn=56433cc41a7d89b7a6772130460005f5&chksm=864e3b8937a1c9bbd230f779eccbf19ab29c1499c71d9ab272121fc03810033c262b024efc28&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1191","LU2488822045.USD","LU1997245177.USD","LU0405327148.USD","01276","LU0359201885.HKD","LU2097828805.USD","BK0028","LU1146622755.USD","LU1781817850.SGD","LU1969619763.USD","LU1997244956.HKD","LU2495084118.USD","LU2097828474.EUR","LU2097828714.EUR","LU2580892862.HKD","600276","BK0060","IPOS","LU2328871848.SGD","LU1064130708.USD","BK0196","LU2097828631.EUR","LU1655091616.SGD","LU1328615791.USD","LU1820825898.SGD","BK1583","LU0405327494.USD","BK0239","LU1255011170.USD","LU2580892789.USD","BK1589","LU2097828557.USD","LU1064131003.USD","LU2289578879.USD","LU1023057109.AUD","03692","LU0359202008.SGD","LU1997245094.SGD","LU2148510915.USD","LU2543165471.USD","BK0183","BK0188","LU1580142542.USD","BK0012","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127853512","title":"恒瑞医药：花旗集团增持，好仓比例升至6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127853512","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127853512?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:23","pubTimestamp":1793870624,"startTime":"0","endTime":"0","summary":"恒瑞医药：花旗集团于2026年10月30日在联交所场内以每股均价0.0000港元买入恒瑞医药（01276）股份42.89万股，涉资约0港元。该笔为场内主动交易，即通过联交所公开市场撮合成交，属二级市场直接买卖。花旗集团此次增持前持有恒瑞医药好仓1524.79万，占比5.9%；增持后持股量为1567.68万，好仓比例升至6.07%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133247438","title":"恒瑞医药：UBS Group AG减持，好仓比例降至4.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133247438","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133247438?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:14","pubTimestamp":1793870080,"startTime":"0","endTime":"0","summary":"2026年10月30日，UBS Group AG以每股均价49.5984港元减持恒瑞医药（01276）股份201.52万股，涉资约9995.07万港元；该笔属场内主动交易，即透过联交所公开市场撮合成交，属于二级市场直接买卖。此次交易后其持股量降至5%以下。UBS Group AG此次减持前持有恒瑞医药好仓1348.74万，占比5.22%；减持后持股量为1147.22万，好仓比例降至4.44%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193137270","title":"恒瑞医药（01276）两款抗肿瘤新药获国家药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1193137270","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193137270?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:56","pubTimestamp":1793786179,"startTime":"0","endTime":"0","summary":"2026年11月4日，江苏恒瑞医药股份有限公司公告称，其子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司已收到国家药品监督管理局签发的《药物临床试验批准通知书》，涉及注射用瑞康曲妥珠单抗及阿得贝利单抗注射液两款产品。恒瑞医药提示，相关药品需完成临床试验并通过国家药监局审评审批后方可上市，研发及注册进程存在不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168364193","title":"恒瑞医药（01276）注射用卡瑞利珠单抗BLA获FDA受理，PDUFA目标日期定于2027年4月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=1168364193","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168364193?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:46","pubTimestamp":1793785595,"startTime":"0","endTime":"0","summary":"2026年11月4日，恒瑞医药公告称，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片，用于不可切除或转移性肝细胞癌一线治疗的生物制品许可申请已获美国食品药品监督管理局受理。根据《处方药用户付费法案》规定，该申请的目标审评日期为2027年4月9日。项目其他进展方面，注射用卡瑞利珠单抗于2021年4月获FDA授予孤儿药资格认定。公司提醒，鉴于FDA现场核查时间及结果的不确定性，本次BLA能否获得最终批准仍存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109143808","title":"恒瑞医药：花旗集团减持，好仓比例降至5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109143808","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109143808?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:25","pubTimestamp":1793784307,"startTime":"0","endTime":"0","summary":"花旗集团于2026年10月29日依据证券借贷协议借出恒瑞医药（01276）H股328.01万股，该安排属于证券借贷，不经联交所公开市场撮合成交，非二级市场直接买卖。花旗集团此次减持前持有恒瑞医药好仓1530.12万，占比5.92%；减持后持股量为1524.79万，好仓比例降至5.9%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680772880","title":"UBS Group AG增持恒瑞医药(01276)111.7万股 每股作价约49.86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680772880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680772880?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:30","pubTimestamp":1793705447,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月28日，UBS Group AG增持恒瑞医药(01276)111.7万股，每股作价49.8626港元，总金额约5569.65万港元。增持后最新持股数目约为1345.74万股，最新持股比例为5.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828474.EUR","LU1064130708.USD","LU1580142542.USD","LU2543165471.USD","LU2328871848.SGD","LU2580892862.HKD","LU1969619763.USD","LU1997244956.HKD","600276","IE0034235071.USD","BK0012","EWH","BK0239","BK1191","LU2495084118.USD","LU2097828557.USD","LU2148510915.USD","LU0359201612.USD","BK0188","BK4118","BK0196","LU0405327148.USD","LU1829250122.USD","LU1655091616.SGD","LU0405327494.USD","BK4585","LU1023057109.AUD","LU1255011170.USD","BK4534","LU1328615791.USD","LU2580892789.USD","LU1863844665.USD","LU1997245094.SGD","BK4588","LU2097828805.USD","LU2097828714.EUR","LU1820825898.SGD","LU0359202008.SGD","LU1064131003.USD","LU1863844749.USD","BK0060","UBS","01276","LU1146622755.USD","LU2488822045.USD","LU0359201885.HKD","LU2289578879.USD","LU1997245177.USD","BK0183","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186978294","title":"恒瑞医药：UBS Group AG增持，好仓比例升至5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186978294","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186978294?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:23","pubTimestamp":1793697836,"startTime":"0","endTime":"0","summary":"UBS Group AG于2026年10月28日在联交所场内以每股均价49.8626港元买入恒瑞医药（01276）股份111.70万股，涉资约5569.65万港元，属场内主动交易，即在二级市场直接买卖股份。UBS Group AG此次增持前持有恒瑞医药好仓1234.04万，占比4.78%；增持后持股量为1345.74万，好仓比例升至5.21%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680744352","title":"花旗集团在恒瑞医药的H股好仓比例下降0.18%至5.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680744352","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680744352?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:23","pubTimestamp":1793697780,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，香港交易所披露信息显示，CitigroupInc.（花旗集团）在恒瑞医药的H股好仓（L）比例于10月28日从6.10%下降至5.92%。同时淡仓（S）比例从2.44%升至2.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920344516.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920344516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0106831901.USD","LU1997245177.USD","LU0072461881.USD","BK0060","LU0405327494.USD","LU1969619763.USD","LU2125154935.USD","LU1146622755.USD","LU0980610538.SGD","LU1997244956.HKD","LU2097828714.EUR","IYF","BK4585","BK4588","LU0314106906.USD","LU2580892862.HKD","LU0130102774.USD","LU2360032135.SGD","LU0162691827.USD","LU2462157665.USD","LU1820825898.SGD","FTXO","LU1244550494.USD","600276","LU0128525689.USD","LU0648001328.SGD","LU1506573853.SGD","01276","LU1255011170.USD","BK4559","BK0183","LU1244550577.SGD","TFNS","LU0359201885.HKD","LU1781817850.SGD","BK0239","LU1668664300.SGD","LU1144417596.USD","LU2543165471.USD","LU0130517989.USD","LU2580892789.USD","LU0320765646.SGD","LU0310800965.SGD","BK4207","LU0203347892.USD","LU0359201612.USD","LU2328871848.SGD","LU0477156953.USD","BK4504","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680075749","title":"贝莱德在恒瑞医药的H股好仓比例上升0.62%至6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680075749","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680075749?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:20","pubTimestamp":1793697600,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在恒瑞医药的H股好仓（L）比例于10月29日从5.89%上升至6.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920336955.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920336955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","BK0012","LU0405327148.USD","LU2097828557.USD","LU2097828714.EUR","LU1580142542.USD","BK1191","BK0028","LU0405327494.USD","BK0196","LU2495084118.USD","LU2328871848.SGD","LU0359201885.HKD","LU2580892862.HKD","LU2097828474.EUR","LU2580892789.USD","600276","LU0359201612.USD","BK0060","LU1820825898.SGD","LU2488822045.USD","LU2543165471.USD","LU2289578879.USD","LU1023057109.AUD","01276","LU2097828805.USD","LU1781817850.SGD","LU1146622755.USD","LU2097828631.EUR","LU1969619763.USD","BK0239","BK0183","LU1997245177.USD","LU1064130708.USD","LU1997245094.SGD","LU0359202008.SGD","LU2148510915.USD","LU1255011170.USD","LU1997244956.HKD","LU1064131003.USD","LU1655091616.SGD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110353172","title":"恒瑞医药：贝莱德增持，好仓比例升至6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110353172","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110353172?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:16","pubTimestamp":1793697408,"startTime":"0","endTime":"0","summary":"贝莱德于2026年10月29日通过取得股份的保证权益增持恒瑞医药（01276）H股160.86万股。该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有恒瑞医药好仓1520.72万，占比5.89%；增持后持股量为1681.58万，好仓比例升至6.51%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148959397","title":"恒瑞医药：花旗集团减持，好仓比例降至5.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148959397","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148959397?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:15","pubTimestamp":1793697356,"startTime":"0","endTime":"0","summary":"花旗集团于2026年10月28日披露，其在证券借贷池中持有的恒瑞医药（01276）股份权益减少，涉及46.75万股；该变化属于证券借贷相关调整，并非在联交所公开市场直接买卖正股。花旗集团此次减持前持有恒瑞医药好仓1576.87万，占比6.1%；减持后持股量为1530.12万，好仓比例降至5.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112845934","title":"恒瑞医药（01276）董事会通过高管任命 张维出任高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1112845934","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112845934?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:12","pubTimestamp":1793697178,"startTime":"0","endTime":"0","summary":"2026年11月3日，恒瑞医药公告称，公司第十届董事会第六次会议以通讯方式召开，11名董事全部出席，会议符合《公司法》及《公司章程》规定。会上，《关于提名聘任公司高级副总裁的议案》获全票通过，表决结果为赞成11票、反对0票、弃权0票。董事会决定自审议通过之日起聘任张维先生为公司高级副总裁，任期至本届董事会届满。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680574790","title":"花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团(01093.HK)及恒瑞医药(01276.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680574790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680574790?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:32","pubTimestamp":1793669529,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0880133367.SGD","LU2039709279.SGD","IE0008368742.USD","BK1521","IE00BZ08YS42.EUR","LU1226287529.USD","IE0008369823.USD","LU1328277881.USD","LU1008478684.HKD","LU1226287875.USD","LU1152091168.USD","BK1574","IE00B031HY20.USD","BK1515","KURE","LU1993786604.SGD","01276","BK1191","09939","LU0140636845.USD","LU1807302812.USD","01093","SG9999004220.SGD","LU2543165471.USD","LU1023057109.AUD","IE00BZ08YR35.GBP","HK0000165453.HKD","01477","LU0314109678.HKD","LU0501845795.SGD","LU1152091754.HKD","LU1813983027.USD","LU1951186391.HKD","LU1960683339.HKD","LU1226288253.USD","LU0315179316.USD","IE00B5MMRT66.SGD","LU0359201885.HKD","IE00B543WZ88.USD","LU0359202008.SGD","LU0326950275.SGD","LU0359201612.USD","LU1226287792.SGD","LU0067412154.USD","LU0072913022.USD","BK1161","IE00BZ08YT58.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185418390","title":"恒瑞医药（01276）披露A股回购进展：已耗资7,388.49万元回购163.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185418390","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185418390?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:33","pubTimestamp":1793612010,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司11月2日发布《关于回购公司A股股份的进展公告》。公告显示，截至2026年10月31日，公司已通过上海证券交易所交易系统以集中竞价方式累计回购A股股份163.62万股，占公司总股本的0.025%，已支付总金额7,388.49万元，实际回购价格区间为每股43.10元至46.33元。恒瑞医药表示，后续将按照相关法规及既定方案，结合市场情况继续实施回购计划，并及时履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680737475","title":"恒瑞医药(01276)截至10月末累计回购A股股份163.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680737475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680737475?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:21","pubTimestamp":1793611281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至2026年10月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购A股股份163.62万股，已回购股份占公司总股本的比例为0.025%，购买的最高价为人民币46.33元/股，最低价为人民币43.10元 /股，已支付的总金额为人民币7,388.49万元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","LU1820825898.SGD","LU1146622755.USD","BK0196","83130","LU0359202008.SGD","LU1255011170.USD","LU2289578879.USD","82822","LU1969619763.USD","82823","LU1328615791.USD","LU2580892789.USD","LU1064130708.USD","LU2097828714.EUR","LU2097828805.USD","02827","82843","07233","03130","82846","LU2328871848.SGD","BK0183","02843","LU1997244956.HKD","LU1655091616.SGD","01276","159982","LU0405327148.USD","LU2580892862.HKD","BK0012","83188","BK0028","LU0359201612.USD","02822","02823","LU1781817850.SGD","LU0359201885.HKD","399300","LU2495084118.USD","03188","LU0405327494.USD","600276","LU1997245177.USD","LU2097828474.EUR","02846","BK1147","LU1580142542.USD","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148869367","title":"恒瑞医药：花旗集团减持，好仓比例降至6.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148869367","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148869367?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:16","pubTimestamp":1793610960,"startTime":"0","endTime":"0","summary":"2026年10月27日，花旗集团收回借出的296.88万恒瑞医药H股股份，该操作属证券借贷安排的归还，并非在联交所公开市场直接买卖。花旗集团此次减持前持有恒瑞医药好仓1600.95万，占比6.2%；减持后持股量为1576.87万，好仓比例降至6.1%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.0623},{"period":"3month","weight":-0.1077},{"period":"6month","weight":-0.1913},{"period":"1year","weight":-0.277},{"period":"ytd","weight":-0.2648}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}